Neurology News

The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically significantly associated with risk for hospitalization for COVID-19 among patients with MS who received the drug before getting COVID-19.

Nearly 50% of individuals with incident mild cognitive impairment diagnoses were considered cognitively normal at follow-up, according to results of a community-based cohort study published in Neurology.

Phase 3 studies of Aduhelm showed amyloid-related imaging abnormalities among approximately 40% of participants, according to study results published in JAMA Neurology.

Messenger RNA COVID-19 vaccination was effective among most patients with MS who used various disease-modifying therapies, according to study results published in Neurology.

Counties with essential health care facilities that had lower ratings on Yelp also had higher mortality rates, data showed.

The World Federation of Neurology has launched the Brain Health Initiative, a program intended to help reduce global burden of brain diseases and disorders.

The Michael J. Fox Foundation for Parkinson’s Research awarded $2 million to a pair of researchers at Yale University for a clinical trial involving ketamine to treat depression in patients with Parkinson’s disease.

Patients with multiple sclerosis were found to have alterations in binocular vision, particularly if optic neuritis was present, according to a study published in Clinical Optometry.

Cognitive behavioral therapy for insomnia may help prevent major depression among older adults with insomnia disorder, according to results of a randomized clinical trial published in JAMA Psychiatry.

Uplizna appeared to benefit patients with neuromyelitis optica spectrum disorder who were previously treated with rituximab, according to study results published in Multiple Sclerosis and Related Disorders.